Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03913117 · ClinicalTrials.gov registry record · Phase 1
Study of Treatment for HPV16+ ASC-US or LSIL
A Phase 1 study of ASC-US and LSIL, sponsored by University of Alabama at Birmingham.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 2
- Study locations
NCT03913117 is a Phase 1 study of ASC-US and LSIL that is actively recruiting participants, run by University of Alabama at Birmingham. The registered enrollment target is 30 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT03913117, a Phase 1 study of ASC-US and LSIL, is actively recruiting participants, sponsored by University of Alabama at Birmingham.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 2
- Study locations
Study Summary
Phase I clinical trial to assess safety of pNGVL4aCRTE6E7L2 DNA and TA-CIN protein vaccinations, and to seek the appropriate dose of the pNGVL4aCRTE6E7L2 DNA vaccine
Interventions
- BIOLOGICAL pNGVL4aCRTE6E7L2
- BIOLOGICAL TA-CIN
Study Locations (2)
Alabama
- UAB | The University of Alabama at Birmingham - Birmingham
Maryland
- Johns Hopkins University - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-07-10 |
| Est. Completion | 2027-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03913117
The ClinicalTrials.gov registry entry for NCT03913117 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with ASC-US appearing as the primary indexed condition, and to 2 interventions - of which pNGVL4aCRTE6E7L2 is the first listed.
NCT03913117 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Alabama, Maryland.
Frequently Asked Questions
What is clinical trial NCT03913117 about?
NCT03913117 is a clinical study titled "Study of Treatment for HPV16+ ASC-US or LSIL". Phase I clinical trial to assess safety of pNGVL4aCRTE6E7L2 DNA and TA-CIN protein vaccinations, and to seek the appropriate dose of the pNGVL4aCRTE6E7L2 DNA vaccine
What is the current status of trial NCT03913117?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2023-07-10. Estimated completion is 2027-09.
What conditions does trial NCT03913117 study?
This clinical trial studies the following conditions: ASC-US, LSIL.
What interventions are being tested in trial NCT03913117?
The interventions under investigation include: pNGVL4aCRTE6E7L2 (BIOLOGICAL), TA-CIN (BIOLOGICAL).
Who is sponsoring clinical trial NCT03913117?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03913117 being conducted?
This trial has 2 study locations across Alabama, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.